NCT03729609View on ClinicalTrials.gov

"Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Untreated CD30-Positive Hodgkin's Lymphoma"

CompletedOBSERVATIONAL

Enrollment

113

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

September 27, 2023

Study Completion Date

September 27, 2023

Conditions

Untreated CD30-Positive Hodgkin's Lymphoma

Interventions

DRUG

Brentuximab vedotin (Genetical Recombination)

Brentuximab vedotin Intravenous Infusion

Trial Locations (1)

Unknown

Takeda Selected Site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY

NCT03729609 - "Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Untreated CD30-Positive Hodgkin's Lymphoma" | Biotech Hunter | Biotech Hunter